

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of Precautions

Itraconazole

May 20, 2025

Therapeutic category

Other chemotherapeutics

Non-proprietary name

Itraconazole

Safety measure

PRECAUTIONS should be revised.

Revised language is underlined.

Current	Revision						
<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving the following drugs: Pimozide, quinidine, bepridil, triazolam, simvastatin, azelnidipine, azelnidipine/olmesartan medoxomil, nisoldipine, ergotamine/cafeine/isopropylantipyrine, dihydroergotamine, ergometrine, methylergometrine, vardenafil, eplerenone, blonanserin, sildenafil (Revatio), tadalafil (Adcirca), suvorexant, ibrutinib, ticagrelor, lomitapide, ivabradine, venetoclax [during its dose escalation phase for relapsed or refractory chronic lymphocytic leukemia (including small lymphocytic lymphoma)], lurasidone hydrochloride, anamorelin hydrochloride, finerenone, isavuconazonium sulfate, aliskiren, dabigatran, rivaroxaban, <u>riociguat</u></p> <p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p>	<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving the following drugs: Pimozide, quinidine, bepridil, triazolam, simvastatin, azelnidipine, azelnidipine/olmesartan medoxomil, nisoldipine, ergotamine/cafeine/isopropylantipyrine, dihydroergotamine, ergometrine, methylergometrine, vardenafil, eplerenone, blonanserin, sildenafil (Revatio), tadalafil (Adcirca), suvorexant, ibrutinib, ticagrelor, lomitapide, ivabradine, venetoclax [during its dose escalation phase for relapsed or refractory chronic lymphocytic leukemia (including small lymphocytic lymphoma)], lurasidone hydrochloride, anamorelin hydrochloride, finerenone, isavuconazonium sulfate, aliskiren, dabigatran, rivaroxaban</p> <p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p>						
<table><tr><th>Drugs</th><th>Signs, symptoms, and treatment</th><th>Mechanism/risk factors</th></tr><tr><td><u>Riociguat</u></td><td><u>Itraconazole may increase the blood concentration of riociguat. (It has been reported as follows: When co-administered with ketoconazole, the AUC and C_{max} of riociguat were increased by 150% and 46%, respectively. In addition, the</u></td><td><u>It is considered that the clearance of riociguat is decreased by the inhibitory activity of itraconazole against CYP3A4 and P-glycoprotein.</u></td></tr></table>	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	<u>Riociguat</u>	<u>Itraconazole may increase the blood concentration of riociguat. (It has been reported as follows: When co-administered with ketoconazole, the AUC and C_{max} of riociguat were increased by 150% and 46%, respectively. In addition, the</u>	<u>It is considered that the clearance of riociguat is decreased by the inhibitory activity of itraconazole against CYP3A4 and P-glycoprotein.</u>	<p>(deleted)</p>
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors					
<u>Riociguat</u>	<u>Itraconazole may increase the blood concentration of riociguat. (It has been reported as follows: When co-administered with ketoconazole, the AUC and C_{max} of riociguat were increased by 150% and 46%, respectively. In addition, the</u>	<u>It is considered that the clearance of riociguat is decreased by the inhibitory activity of itraconazole against CYP3A4 and P-glycoprotein.</u>					

	<u>elimination half-life was prolonged, and the clearance was also decreased.)</u>							
<p>10.2 Precautions for Co-administration (This drug should be administered with caution when co-administered with the following.)</p> <p>(N/A)</p>								
<p>10.2 Precautions for Co-administration (This drug should be administered with caution when co-administered with the following.)</p> <table border="1"> <thead> <tr> <th>Drugs</th><th>Signs, symptoms, and treatment</th><th>Mechanism/risk factors</th></tr> </thead> <tbody> <tr> <td><u>Riociguat</u></td><td><u>Itraconazole may increase the blood concentration of riociguat. (It has been reported as follows: When co-administered with ketoconazole, the AUC and C_{max} of riociguat were increased by 150% and 46%, respectively. In addition, the elimination half-life was prolonged.) When co-administration with itraconazole is necessary, patients should be monitored for their condition and dose reduction of riociguat should be considered as necessary.</u></td><td><u>It is considered that the clearance of riociguat is decreased by the inhibitory activity of itraconazole against CYP1A1 and CYP3A4.</u></td></tr> </tbody> </table>			Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	<u>Riociguat</u>	<u>Itraconazole may increase the blood concentration of riociguat. (It has been reported as follows: When co-administered with ketoconazole, the AUC and C_{max} of riociguat were increased by 150% and 46%, respectively. In addition, the elimination half-life was prolonged.) When co-administration with itraconazole is necessary, patients should be monitored for their condition and dose reduction of riociguat should be considered as necessary.</u>	<u>It is considered that the clearance of riociguat is decreased by the inhibitory activity of itraconazole against CYP1A1 and CYP3A4.</u>
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors						
<u>Riociguat</u>	<u>Itraconazole may increase the blood concentration of riociguat. (It has been reported as follows: When co-administered with ketoconazole, the AUC and C_{max} of riociguat were increased by 150% and 46%, respectively. In addition, the elimination half-life was prolonged.) When co-administration with itraconazole is necessary, patients should be monitored for their condition and dose reduction of riociguat should be considered as necessary.</u>	<u>It is considered that the clearance of riociguat is decreased by the inhibitory activity of itraconazole against CYP1A1 and CYP3A4.</u>						

(N/A) Not Applicable. No corresponding language is included in the current PRECAUTIONS.